{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:51:53Z","timestamp":1773445913342,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global population is aging rapidly, creating a growing demand for cardiovascular care that is better aligned with the complex comorbidities and diverse life contexts of older adults. The 5Ms of geriatrics\u2014Mind, Mobility, Medications, Multicomplexity, and What Matters Most\u2014provide a practical framework to individualize treatment strategies based on functional status, comorbidities, and patient values (ikigai). This review explores how integrating the 5Ms into the management of hypertension, atrial fibrillation, and heart failure can guide clinical decision-making in aging societies. We highlight practical strategies, such as deprescribing, fall risk assessment, and shared decision-making, that tailor care to patient priorities. Furthermore, we discuss policy implications, including the need for greater incentives for comprehensive geriatric assessments and advance care planning. Since evidence-based guidelines may not fully capture the complexity of older patients, incorporating the 5Ms and comprehensive assessments can support patient-centered care and help build evidence based on meaningful outcomes in aging societies.<\/jats:p>","DOI":"10.1038\/s41440-025-02396-5","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:36:25Z","timestamp":1760693785000},"page":"3172-3178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ikigai in aging hearts: Japan\u2019s approach to cardiovascular care"],"prefix":"10.1038","volume":"48","author":[{"given":"Ryo","family":"Nakamaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2020.104220","volume":"91","author":"H Murayama","year":"2020","unstructured":"Murayama H, Kobayashi E, Okamoto S, Fukaya T, Ishizaki T, Liang J, et al. National prevalence of frailty in the older Japanese population: Findings from a nationally representative survey. Arch Gerontol Geriatr. 2020;91:104220.","journal-title":"Arch Gerontol Geriatr"},{"key":"2396_CR2","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/jgs.14979","volume":"65","author":"M Tinetti","year":"2017","unstructured":"Tinetti M, Huang A, Molnar F. The Geriatrics 5M\u2019s: A New Way of Communicating What We Do. J Am Geriatr Soc. 2017;65:2115\u20132115.","journal-title":"J Am Geriatr Soc"},{"key":"2396_CR3","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1007\/s11606-023-08364-4","volume":"38","author":"S Hamada","year":"2023","unstructured":"Hamada S, Iwagami M, Sakata N, Hattori Y, Kidana K, Ishizaki T, et al. Changes in Polypharmacy and Potentially Inappropriate Medications in Homebound Older Adults in Japan, 2015\u20132019: a Nationwide Study. J Gen Intern Med. 2023;38:3517\u201325.","journal-title":"J Gen Intern Med"},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2396_CR5","unstructured":"Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (in Japanese). Japanese Soc Hypertens. 2025. (in press)"},{"key":"2396_CR6","doi-asserted-by":"publisher","first-page":"06480","DOI":"10.1016\/j.jacc.2025.05.007","volume":"S0735-1097","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;S0735-1097:06480\u20130. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007.","journal-title":"J Am Coll Cardiol"},{"key":"2396_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/ggi.14005","volume":"20","author":"S Satake","year":"2020","unstructured":"Satake S, Arai H. The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria). Geriatr Gerontol Int. 2020;20:992\u20133.","journal-title":"Geriatr Gerontol Int"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","volume":"14","author":"D O\u2019Mahony","year":"2023","unstructured":"O\u2019Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14:625\u201332.","journal-title":"Eur Geriatr Med"},{"key":"2396_CR9","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71:2052\u201381.","journal-title":"J Am Geriatr Soc"},{"key":"2396_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fphar.2020.00570","volume":"11","author":"K Graves-Morris","year":"2020","unstructured":"Graves-Morris K, Stewart C, Soiza RL, Taylor-Rowan M, Quinn TJ, Loke YK, et al. The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: a systematic review and meta-analysis. Front Pharm. 2020;11:570.","journal-title":"Front Pharm"},{"key":"2396_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","volume":"15","author":"MS Salahudeen","year":"2015","unstructured":"Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.","journal-title":"BMC Geriatr"},{"key":"2396_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ggi.15001","volume":"25","author":"F Mizokami","year":"2025","unstructured":"Mizokami F, Mizuno T, Taguchi R, Nasu I, Arai S, Higashi K, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25:5\u201313.","journal-title":"Geriatr Gerontol Int"},{"key":"2396_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ggi.14619","volume":"23","author":"S Yamada","year":"2023","unstructured":"Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23:558\u201364.","journal-title":"Geriatr Gerontol Int"},{"key":"2396_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamainternmed.2022.1657","volume":"182","author":"T Chen","year":"2022","unstructured":"Chen T, Shao F, Chen K, Wang Y, Wu Z, Wang Y, et al. Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials. JAMA Intern Med. 2022;182:660\u20137.","journal-title":"JAMA Intern Med"},{"key":"2396_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827\u201334.","journal-title":"JAMA Intern Med"},{"key":"2396_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","volume":"122","author":"P Verdecchia","year":"2018","unstructured":"Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122:352\u201368.","journal-title":"Circ Res"},{"key":"2396_CR17","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.120.14766","volume":"75","author":"EZ Soliman","year":"2020","unstructured":"Soliman EZ, Rahman AF, Zhang ZM, Rodriguez CJ, Chang TI, Bates JT, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020;75:1491\u20136.","journal-title":"Hypertension"},{"key":"2396_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/europace\/euac123","volume":"25","author":"I Savelieva","year":"2023","unstructured":"Savelieva I, Fumagalli S, Kenny RA, Anker S, Benetos A, Boriani G, et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2023;25:1249\u201376.","journal-title":"Europace"},{"key":"2396_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamainternmed.2021.1819","volume":"181","author":"GM Ouellet","year":"2021","unstructured":"Ouellet GM, Fried TR, Gilstrap LG, O\u2019Leary JR, Austin AM, Skinner JS, et al. Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life. JAMA Intern Med. 2021;181:1121\u20133.","journal-title":"JAMA Intern Med"},{"key":"2396_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1253\/circrep.CR-20-0082","volume":"2","author":"M Akao","year":"2020","unstructured":"Akao M, Shimizu W, Atarashi H, Ikeda T, Inoue H, Okumura K, et al. Oral anticoagulant use in elderly Japanese patients with non-valvular atrial fibrillation \u2015 subanalysis of the ANAFIE Registry \u2015. Circ Rep. 2020;2:552\u20139.","journal-title":"Circ Rep"},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020;383:1735\u201345.","journal-title":"N Engl J Med"},{"key":"2396_CR22","first-page":"279","volume":"149","author":"LPT Joosten","year":"2024","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, K\u00f6hlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149:279\u201389.","journal-title":"Circulation"},{"key":"2396_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/joa3.13038","volume":"40","author":"K Soejima","year":"2024","unstructured":"Soejima K, Nogami A, Kumagai K, Uno K, Kurita T, Morishima I, et al. Impact of frailty in patients with non-valvular atrial fibrillation undergoing catheter ablation. J Arrhythmia. 2024;40:463\u201371.","journal-title":"J Arrhythmia"},{"key":"2396_CR24","doi-asserted-by":"publisher","first-page":"e002641","DOI":"10.1136\/openhrt-2024-002641","volume":"11","author":"M Lobeek","year":"2024","unstructured":"Lobeek M, Middeldorp ME, Van Gelder IC, Rienstra M. Multimorbidity in patients with atrial fibrillation. Open Heart. 2024;11:e002641.","journal-title":"Open Heart"},{"key":"2396_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010642","volume":"17","author":"R Nakamaru","year":"2024","unstructured":"Nakamaru R, Nishimura S, Kumamaru H, Shoji S, Nakatani E, Yamamoto H, et al. Trajectories of frailty and clinical outcomes in older adults with atrial fibrillation: insights from the Shizuoka Kokuho database. Circ Cardiovasc Qual Outcomes. 2024;17:e010642.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2396_CR26","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jamainternmed.2019.4235","volume":"179","author":"ME Tinetti","year":"2019","unstructured":"Tinetti ME, Naik AD, Dindo L, Costello DM, Esterson J, Geda M, et al. Association of patient priorities\u2013aligned decision-making with patient outcomes and ambulatory health care burden among older adults with multiple chronic conditions: a nonrandomized clinical trial. JAMA Intern Med. 2019;179:1688\u201397.","journal-title":"JAMA Intern Med"},{"key":"2396_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"2396_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/jch.14004","volume":"22","author":"M Camafort","year":"2020","unstructured":"Camafort M, Kario K. Hypertension, heart failure, and frailty in older people: a common but unclear situation. J Clin Hypertens. 2020;22:1763\u20138.","journal-title":"J Clin Hypertens"},{"key":"2396_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jacc.2021.07.014","volume":"78","author":"A Pandey","year":"2021","unstructured":"Pandey A, Shah SJ, Butler J, Kellogg DL Jr, Lewis GD, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021;78:1166\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"2396_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427\u201337.","journal-title":"N Engl J Med"},{"key":"2396_CR31","doi-asserted-by":"publisher","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J. 2025:CJ-25-0002. https:\/\/doi.org\/10.1253\/circj.CJ-25-0002.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"2396_CR32","doi-asserted-by":"publisher","first-page":"e078188","DOI":"10.1136\/bmj-2023-078188","volume":"387","author":"HJ Woodford","year":"2024","unstructured":"Woodford HJ, McKenzie D, Pollock LM. Appropriate management of heart failure in older people with frailty. BMJ. 2024;387:e078188.","journal-title":"BMJ"},{"key":"2396_CR33","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64\u2013S74.","journal-title":"Diabetes Care"},{"key":"2396_CR34","doi-asserted-by":"publisher","unstructured":"Stolfo D, Iacoviello M, Chioncel O, Anker MS, Bayes-Genis A, Braunschweig F, et al. How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3642.","DOI":"10.1002\/ejhf.3642"},{"key":"2396_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ehf2.14245","volume":"10","author":"R Nakamaru","year":"2022","unstructured":"Nakamaru R, Shiraishi Y, Sandhu AT, Heidenreich PA, Shoji S, Kohno T, et al. Cardiovascular vs. non-cardiovascular deaths after heart failure hospitalization in young, older, and very old patients. ESC Heart Fail. 2022;10:673\u201384.","journal-title":"ESC Heart Fail"},{"key":"2396_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572\u201380.","journal-title":"Lancet"},{"key":"2396_CR37","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","volume":"71","author":"EZ Gorodeski","year":"2018","unstructured":"Gorodeski EZ, Goyal P, Hummel SL, Krishnaswami A, Goodlin SJ, Hart LL, et al. Domain management approach to heart failure in the geriatric patient : present and future. J Am Coll Cardiol. 2018;71:1921\u201336.","journal-title":"J Am Coll Cardiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02396-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:41Z","timestamp":1764889301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02396-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02396-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MS has been partially supported by research funding from Polybio, Pfizer in the past three years, and Novartis. He has also received lecture honoraria from Boehringer Ingelheim. KY has been supported by research funding from Boehringer Ingelheim, Novartis, and Eli Lilly. He has also received lecture honoraria from DAIICHI SANKYO, INC., Novartis, and Otsuka Pharmaceutical Co., Ltd. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}